Clinical Trials on Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES in Hungary

Total 11 results

Implantica CE Reflux Ltd.

Active, not recruiting

Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of GERD

GERD

Hungary, Serbia
Takeda

Completed

Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

GERD

Hungary, Austria, Germany, Australia
AstraZeneca

Completed

ASTERIX: Low Dose ASA and Nexium

Gastroesophageal Reflux

Bulgaria, Italy, South Africa, Spain, Hungary, Canada, Hong Kong, Greece, Germany, Australia, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Eisai Inc.

Completed

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Gastroesophageal Reflux

United States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
AstraZeneca

Completed

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Gastroesophageal Reflux Disease (GERD)

Hungary, Romania, Norway, Belgium, France, Netherlands, Germany, Australia
Takeda

Completed

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)

Gastroesophageal Reflux

Hungary, Austria, Germany, Poland
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

Gastroesophageal Reflux Disease | Erosive Esophagitis

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Gastroesophageal Reflux Disease

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer (NSCLC)

United States, United Kingdom, Belgium, Hungary, Denmark

Clinical Trials on Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations